Navigation Links
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
Date:3/9/2009

VALENCIA, Calif., March 9 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into agreements with Pfizer Inc. (NYSE: PFE) to purchase Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery. The aggregate purchase price is $33 million, subject to certain adjustments. At MannKind's option, up to $30 million worth of the company's common stock may be issued to Pfizer at closing and applied toward the full purchase price. The transfer of certain real property rights pursuant to this transaction will require the consent of third parties.

Upon the closing of this transaction, MannKind intends to retain more than half of the current workforce, subject to consultation with the works council and employee co-determination rights, and plans to operate the facility at a production level commensurate with the company's present needs for recombinant human insulin.

In the event some or all of the third-party consents are not obtained, only the bulk insulin, the license to manufacture bulk insulin for use in pulmonary delivery and, potentially, certain removable equipment will be transferred to MannKind at closing.

"The insulin plant in Frankfurt is a state-of-the-art insulin production facility that would make an excellent counterpart to our formulation, fill and finish facility for AFRESA in Danbury, Connecticut," said Alfred Mann, Chairman and Chief Executive Officer of MannKind Corporation. "Upon the closing of this transaction, we will
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
2. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
5. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
6. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
7. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
8. MannKind to Present at the UBS Global Life Sciences Conference
9. MannKind Corporation Reports Second Quarter Financial Results
10. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
11. MannKind to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... A novel combination of microscopy and data processing has ... National Laboratory an unprecedented look at the surface of ... properties. , The research team led by ORNL,s ... a perovskite manganite, a complex material that exhibits dramatic ... surface behavior could benefit researchers who are interested in ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... October 1 , - "Expert Consult" ... Content is Always Current, Elsevier, the ... the publication of the 40th edition of ... Gray,s Anatomy: The Anatomical Basis of Clinical,Practice ...
... product design and development, manufacture, and distribution ... ... 1 Cylex has announced receipt of,certification to ISO ... Canadian Medical Devices Conformity Assessment,System (CMDCAS). These certifications signify ...
... Sept. 30 NxStage Medical,Inc. (Nasdaq: NXTM ), ... Jeffrey H. Burbank, Chief Executive Officer,and Robert S. Brown, ... Healthcare Focus Conference on October 6, 2008 at Le ... is scheduled for Monday, October 6th at,2:30 p.m. ET. ...
Cached Biology Technology:New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 2New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 3Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... As the human population increases, so too do the ... issue of International Journal of Plant Sciences , ... Sarah Assmann explores how the responses to environmental stresses ... possible approaches to addressing growing human demand for crop ...
... despite the yuck factor, have captured the hearts of two ... team that this week is publishing the leech,s complete genome ... Weisblat, a UC Berkeley professor of molecular and cell biology ... sequencing initiative that has targeted a variety of animals in ...
... the quest to find the easiest and fastest way to ... In an article published in Frontiers in Microbiology on ... polymerase chain reaction (PCR) system to discover specific gene targets ... show that assays performed using this PCR system are rapid, ...
Cached Biology News:Can observations of a hardy weed help feed the world? 2What do leeches, limpets and worms have in common? Now, a sequenced genome 2What do leeches, limpets and worms have in common? Now, a sequenced genome 3USDA explores using novel genetic labs for faster detection of E. coli 2
Request Info...
...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: